Azra AI

What do the vendor's pages sell today?

The homepage lists Radiology for incidental findings, Oncology, Clinical Research, Cardiology (structural heart) and ED Discharge Coordination, plus advisory services for navigation, tumor board and cancer registry case finding. The About page calls it "a healthcare enterprise platform that operationalizes underutilized data" and mentions agentic AI, multimodal data integration and workflow automation. The pages list tumor board and multidisciplinary case review, registry automation and trial pre-screening among the tasks. How the AI reads source documents, by NLP or a large language model, is not described.

The press page announces two acquisitions: Thynk Health on April 28, 2026, for lung screening and incidental findings, and Blackford Analysis on October 20, 2026, an imaging AI platform. Partnerships with Blackford (August 5, 2026) and 4DMedical (August 17, 2026) were announced first. Blackford Analysis Ltd., whose acquisition was announced in October 2026, holds an older 510(k), K142337, cleared on March 19, 2015 as the Blackford Analysis Registration Product Family (product code LLZ).

Who is behind it?

Azra AI is at 1316 Adams Street, Suite 220, Nashville, though some aggregators list Franklin, Tennessee. The company does not state a founding year. PitchBook says 2021 and Tracxn 2022, and PitchBook gives a former name, Invenero Holdings. The About page names John Marshall as CEO, Brook Blackmore as Chief Strategy and Product Officer, Ryan King as CTO and Joey Bargo as CMIO.

Funding figures come only from aggregators and conflict, from $7.95 million over two rounds (Tracxn) to $18.9 million including an $11 million Series A dated January 23, 2026 (PitchBook), with a $10.5 million Form D dated April 24, 2026 reported separately. Named investors are Connexa Capital, NewHealth Ventures, SJF Ventures, FCA Venture Partners and Sopris. The homepage says it is integrated with leading EHRs and names none.

What do the pages say about security, evidence and price?

None of HIPAA, a BAA, SOC 2, HITRUST or ISO 27001 appears among the claims on the homepage, About page or press page. No paper on Azra AI appears in PubMed. A price is not published, and the site offers a demo request.

The verdict

The platform is sold by demo request across oncology, imaging, cardiology, ED discharge and trials. The homepage claims more than 1,500 sites while the About page speaks of hundreds of health systems, so customer scale is not settled. An imaging group that wants a cleared algorithm under Azra's own name has no such record to cite.